But again, there have also been disappointments with some of these new targeted interventions like alpha-synuclein antibodies or substrate reduction therapies for glucocerebrosidase enzyme in GBA-positive patients with PD [90–92], suggesting a need for alternative approaches. This evidence concerns the gene GBA1 and Parkinson disease.